The sensitivity and specificity of a new formula to distinguish endometrioid type endometrial carcinoma from ovarian endometrial carcinoma

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 148, Issue 1, 2010, Pages 67-72

  Nishimura, Sadako ^a   Ito, Yoichi M ^b   Tsuda, Hiroshi ^c   Ohnishi, Yoshitaka ^d   Kataoka, Fumio ^c   Nomura, Hiroyuki ^c   Chiyoda, Tatsuyuki ^c   Suzuki, Atsushi ^c   Susumu, Nobuyuki ^c   Aoki, Daisuke ^c   Hatae, Masayuki ^d  

^a OSAKA CITY GENERAL HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d Kagoshima City Hospital   (Japan)

Author keywords

Cyclin A; Cyclin B1; Cyclin D1; Cyclin E; Cyclin F; KI67

Indexed keywords

CYCLINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

EID: 72049132610     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2009.09.016     Document Type: Article

References (12)

1. William J.H., Carlos A.P., and Robert C.Y. Principles and practice of gynecologic oncology. 3rd ed. (2000), Lippincott Williams & Wilkins p. 917-30, p. 995-1006
2. Zwart J., Geisler J.P., and Geisler H.E. Five-year survival in patients with endometrioid carcinoma of the ovary versus those with serous carcinoma. Eur J Gynaecol Oncol 19 3 (1998) 225-228
3. Scully R.E., Young R.H., and Clement P.B. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Atlas of tumor pathology. 3rd ed. (1998), Armed Forces Institute of Pathology, Bethesda, MD p. 107-40
4. Shedden K.A., Kshirsagar M.P., Schwartz D.R., et al. Histologic type, organ of origin, and Wnt pathway status: effect of gene expression in ovarian and uterine carcinoma. Clin Cancer Res (2005) 2131-2132
5. Nishimura S., Tsuda H., Hashiguchi Y., et al. Comparison of cyclin expression between endometrioid-type endometrial cancer and endometrioid ovarian cancer. J Clin Oncol 22 14S (2004) 5013
6. Bossuyt P.M., Reitsma J.B., Bruns D.E., et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STRAD initiative. BMJ 326 (2004) 41-44
7. Machin D., Campbell M.J., Fayers P.M., and Pinol A.P.Y. Sample size tables for clinical studies. 2nd ed. (1997), Blackwell Science
8. Obata K., Morland S.J., Watson R.H., et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58 (1998) 2095-2097
9. Tashiro H., Blazes M.S., Wu R., et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57 (1997) 3935-3940
10. Lax S.F., Kendall B., Tashiro H., Slebos R.J., and Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88 (2000) 814-824
11. Sato N., Tsunoda H., Nishida M., et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 60 (2000) 7052-7056
12. Hashiguchi Y., Tsuda H., Yamamoto K., Inoue T., Ishiko O., and Ogita S. Combined analysis of p53 and RB pathways in epithelial ovarian cancer. Human Pathol 32 (2001) 988-996